LISINOPRIL and HYDROCHLOROTHIAZIDE NDC 51407-564

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-564Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0564Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-564-05	51407056405	500 TABLET in 1 BOTTLE (51407-564-05)Marketed from Feb 15, 2025
51407-564-90	51407056490	90 TABLET in 1 BOTTLE (51407-564-90)Marketed from Feb 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): LISINOPRIL and HYDROCHLOROTHIAZIDE
Generic name (nonproprietary): lisinopril and hydrochlorothiazide
Active ingredients: Lisinopril — 10 mg/1Hydrochlorothiazide — 12.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: GSMS, Incorporated
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076674
Marketing start: Feb 15, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)Increased Diuresis (Physiologic effect)Thiazides (Chemical structure)
Identifiers: Product ID 51407-564_fd91c3d4-99e0-4b5d-8f6c-d08f19b64703SPL ID fd91c3d4-99e0-4b5d-8f6c-d08f19b64703SPL set ID d02a0d38-676a-4e0f-9aa2-0a6c56cd7361RxCUI 197885, 197886, 197887UNII E7199S1YWR, 0J48LPH2THUPC 0351407565907, 0351407566904, 0351407565051, 0351407566058, 0351407564054, 0351407564900
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor; Thiazide Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407056405 followed by a unit qualifier and the quantity

Package 51407-0564-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 15, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Lisinopril and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will requ…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076674

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076674
Product	Strength	Form · route	Labeler	Product NDC
LISINOPRIL and HYDROCHLOROTHIAZIDE	Lisinopril 20 mg/1; Hydrochlorothiazide 12.5 mg/1	TabletOral	GSMS, Incorporated	51407-565
LISINOPRIL and HYDROCHLOROTHIAZIDE	Lisinopril 20 mg/1; Hydrochlorothiazide 25 mg/1	TabletOral	GSMS, Incorporated	51407-566